X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1190) 1190
female (1159) 1159
index medicus (1150) 1150
middle aged (870) 870
aged (707) 707
oncology (664) 664
ovarian neoplasms - pathology (640) 640
adult (626) 626
cystadenocarcinoma, serous - pathology (625) 625
prognosis (597) 597
cystadenocarcinoma, serous - mortality (569) 569
ovarian neoplasms - mortality (541) 541
neoplasm staging (512) 512
ovarian cancer (478) 478
cancer (442) 442
survival rate (392) 392
aged, 80 and over (367) 367
carcinoma (360) 360
obstetrics & gynecology (356) 356
retrospective studies (311) 311
follow-up studies (283) 283
survival (282) 282
chemotherapy (271) 271
cystadenocarcinoma, serous - genetics (266) 266
ovarian neoplasms - genetics (252) 252
surgery (217) 217
neoplasm grading (202) 202
adenocarcinoma, clear cell - mortality (201) 201
cystadenocarcinoma, serous - metabolism (198) 198
ovarian neoplasms - drug therapy (196) 196
cystadenocarcinoma, serous - drug therapy (191) 191
endometrial neoplasms - mortality (189) 189
endometrial neoplasms - pathology (188) 188
adenocarcinoma, clear cell - pathology (186) 186
cystadenocarcinoma, serous - surgery (185) 185
ovarian neoplasms - metabolism (183) 183
tumors (180) 180
ovarian neoplasms - surgery (171) 171
pathology (168) 168
immunohistochemistry (167) 167
adenocarcinoma, mucinous - pathology (161) 161
adenocarcinoma, mucinous - mortality (159) 159
survival analysis (156) 156
analysis (152) 152
antineoplastic combined chemotherapy protocols - therapeutic use (146) 146
expression (138) 138
treatment outcome (134) 134
disease-free survival (132) 132
research (121) 121
cystadenocarcinoma, serous - therapy (120) 120
neoplasm recurrence, local - pathology (119) 119
endometrial cancer (115) 115
combined modality therapy (114) 114
adenocarcinoma (112) 112
neoplasm recurrence, local - mortality (109) 109
abridged index medicus (105) 105
ovarian neoplasms - therapy (102) 102
young adult (102) 102
care and treatment (101) 101
women (100) 100
neoplasm invasiveness (98) 98
cystadenocarcinoma, serous - diagnosis (96) 96
breast-cancer (95) 95
health aspects (94) 94
medicine & public health (92) 92
metastasis (92) 92
male (91) 91
ovarian carcinoma (90) 90
adenocarcinoma, clear cell - surgery (89) 89
diagnosis (89) 89
adolescent (88) 88
biomarkers, tumor - metabolism (87) 87
obstetrics and gynecology (86) 86
hematology, oncology and palliative medicine (85) 85
gene expression (84) 84
kaplan-meier estimate (84) 84
cystadenocarcinoma, papillary - pathology (83) 83
carcinoma, endometrioid - mortality (80) 80
gene expression regulation, neoplastic (80) 80
article (79) 79
cystadenocarcinoma, papillary - mortality (79) 79
cisplatin (77) 77
management (77) 77
risk factors (77) 77
carcinoma, endometrioid - pathology (76) 76
endometrial neoplasms - surgery (76) 76
mutation (76) 76
ovarian neoplasms - diagnosis (76) 76
adenocarcinoma, mucinous - surgery (75) 75
cystadenocarcinoma, serous - secondary (74) 74
proportional hazards models (74) 74
uterine neoplasms - mortality (74) 74
uterine neoplasms - pathology (74) 74
chemotherapy, adjuvant (72) 72
genetic aspects (72) 72
mortality (72) 72
lymphatic metastasis (70) 70
gynecologic-oncology-group (65) 65
immunoenzyme techniques (64) 64
paclitaxel - administration & dosage (64) 64
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1155) 1155
Chinese (23) 23
German (13) 13
Japanese (11) 11
Russian (9) 9
French (3) 3
Romanian (2) 2
Bulgarian (1) 1
Italian (1) 1
Polish (1) 1
Portuguese (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 11, pp. 1579 - 1589
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2015, Volume 33, Issue 34, pp. 4015 - 4022
Journal Article
Cancer Cell, ISSN 1535-6108, 02/2013, Volume 23, Issue 2, pp. 186 - 199
Integrated genomic analyses revealed a miRNA-regulatory network that further defined a robust integrated mesenchymal subtype associated with poor overall... 
TRANSITION | LUNG-CANCER | CELLS | EPITHELIAL PHENOTYPE | METASTASIS | GENE | ONCOLOGY | STATISTICS | MIR-200 FAMILY | EXPRESSION | CHALLENGES | CELL BIOLOGY | Prognosis | Cadherins - metabolism | Apoptosis - drug effects | Vimentin - metabolism | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Ovarian Neoplasms - pathology | Gene Expression Profiling | Cystadenocarcinoma, Serous - genetics | Ovarian Neoplasms - mortality | Cystadenocarcinoma, Serous - pathology | Epithelial-Mesenchymal Transition - genetics | Immunoenzyme Techniques | Ovarian Neoplasms - genetics | Neoplasm Grading | Vimentin - genetics | Female | Tumor Cells, Cultured | Cadherins - genetics | Real-Time Polymerase Chain Reaction | Snail Family Transcription Factors | RNA, Messenger - genetics | Survival Rate | Transcription Factors - genetics | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | Transcription Factors - metabolism | Animals | Transforming Growth Factor beta - genetics | Mice, Nude | Cystadenocarcinoma, Serous - mortality | Biomarkers, Tumor - genetics | Cell Proliferation - drug effects | Mesoderm - metabolism | Mice | MicroRNAs - genetics | Mesoderm - pathology | Transforming Growth Factor beta - metabolism | Cell Movement | MicroRNA | Analysis | Genomics | Stem cells | Genetic research | Transforming growth factors | Ovarian cancer | Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 11/2013, Volume 8, Issue 11, pp. e80063 - e80063
Ovarian cancer is an immune reactive malignancy with a complex immune suppressive network that blunts successful immune eradication. This suppressive... 
GYNECOLOGIC-ONCOLOGY-GROUP | NEU-TRANSGENIC MICE | PROGNOSTIC-FACTORS | REGULATORY CELLS | DENDRITIC CELLS | MULTIDISCIPLINARY SCIENCES | TRANSCRIPTION FACTOR FOXP3 | TUMOR | INDUCTION | AUTOIMMUNE-DISEASE | CARCINOMA | CD8-Positive T-Lymphocytes - pathology | Prognosis | Humans | Middle Aged | Ovarian Neoplasms - pathology | Cystadenocarcinoma, Serous - genetics | Ovarian Neoplasms - mortality | CD4-Positive T-Lymphocytes - pathology | Cystadenocarcinoma, Serous - pathology | T-Lymphocytes, Regulatory - pathology | T-Lymphocytes, Regulatory - immunology | CD4-Positive T-Lymphocytes - immunology | Ovarian Neoplasms - genetics | Interleukin-2 Receptor alpha Subunit - genetics | Aged, 80 and over | Adult | Female | Cystadenocarcinoma, Serous - immunology | Interleukin-2 Receptor alpha Subunit - immunology | Gene Expression | Ovary - pathology | Ovary - immunology | Immunophenotyping | Survival Analysis | Cystadenocarcinoma, Serous - mortality | Lymphocyte Count | Aged | CD8-Positive T-Lymphocytes - immunology | Forkhead Transcription Factors | Ovarian Neoplasms - immunology | Transcription factors | Ovarian carcinoma | CD8 antigen | Effector cells | Cytotoxicity | Lymphocytes T | Malignancy | Clinical outcomes | Ovarian cancer | Immunology | Lymphocytes | Immunotherapy | CD25 antigen | Foxp3 protein | Cell survival | Immunoregulation | Histology | CD3 antigen | Patients | Survival | CD4 antigen | Studies | Chemotherapy | Medical prognosis | Immunofluorescence | Cancer | Tumors | Index Medicus
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2015, Volume 21, Issue 7, pp. 1574 - 1582
Journal Article
Journal Article
by Sieh, Weiva, PhD and Köbel, Martin, Dr and Longacre, Teri A, Prof and Bowtell, David D, Prof and deFazio, Anna, PhD and Goodman, Marc T, PhD and Høgdall, Estrid, PhD and Deen, Suha, Prof and Wentzensen, Nicolas, MD and Moysich, Kirsten B, Prof and Brenton, James D, MD and Clarke, Blaise A, MD and Menon, Usha, Prof and Gilks, C Blake, Prof and Kim, Andre, MPH and Madore, Jason, MS and Fereday, Sian, BSc and George, Joshy, MEng and Galletta, Laura, BSc and Lurie, Galina, MD and Wilkens, Lynne R, DrPH and Carney, Michael E, MD and Thompson, Pamela J, MPH and Matsuno, Rayna K, PhD and Kjær, Susanne Krüger, Prof and Jensen, Allan, PhD and Høgdall, Claus, Prof and Kalli, Kimberly R, PhD and Fridley, Brooke L, PhD and Keeney, Gary L, MD and Vierkant, Robert A, MS and Cunningham, Julie M, PhD and Brinton, Louise A, PhD and Yang, Hannah P, PhD and Sherman, Mark E, MD and García-Closas, Montserrat, Prof and Lissowska, Jolanta, PhD and Odunsi, Kunle, Prof and Morrison, Carl, MD and Lele, Shashikant, Prof and Bshara, Wiam, MD and Sucheston, Lara, PhD and Jimenez-Linan, Mercedes, MD and Driver, Kristy, BSc and Alsop, Jennifer, BA and Mack, Marie and McGuire, Valerie, PhD and Rothstein, Joseph H, MS and Rosen, Barry P, Prof and Bernardini, Marcus Q, MD and Mackay, Helen, MD and Oza, Amit, Prof and Wozniak, Eva L, BSc and Benjamin, Elizabeth, MD and Gentry-Maharaj, Aleksandra, PhD and Gayther, Simon A, Prof and Tinker, Anna V, MD and Prentice, Leah M, PhD and Chow, Christine, BMLSc and Anglesio, Michael S, PhD and Johnatty, Sharon E, PhD and Chenevix-Trench, Georgia, Prof and Whittemore, Alice S, Prof and Pharoah, Paul DP, Prof and Goode, Ellen L, PhD and Huntsman, David G, Prof and Ramus, Susan J, PhD
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 9, pp. 853 - 862
Journal Article
Cancer, ISSN 0008-543X, 04/2017, Volume 123, Issue 7, pp. 1144 - 1155